Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced it received regulatory approval to initiate KLARITY, a Phase 2 clinical trial to investigate KIO-104 in patients ...

Bayer seeks European approval of extended 6-month treatment interval for Eylea 8 mg to treat nAMD & diabetic macular edema: Berlin Tuesday, February 11, 2025, 10:00 Hrs [IST] Baye ...

February is Age-Related Macular Degeneration Awareness (AMD) month. While AMD might be unfamiliar to some, nearly half a million people in Quebec are affected by this disease, which is the leading ...

Regeneron Pharmaceuticals has announced results from the phase 3 QUASAR trial and its extension study of the phase 3 PULSAR ...

These are the best vitamins and supplements for eye health, which are great for supporting your vision and helping you take ...

Loss to follow-up higher among men who are Black or Hispanic, or those who must travel farther to care facilities.

D Molecular Therapeutics reported 52-week Phase 2b data for 4D-150 in wet AMD, showing sustained visual acuity improvements.

As people get older, two of the biggest health concerns are dementia and eye diseases like macular degeneration and cataracts ...

ALPHARETTA, Ga. - Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company with a market capitalization of $85.7 million focused on developing therapies for ocular diseases, has announced ...

Multiple subcutaneous doses safe and well-tolerated >69% reduction in anti-VEGF intravitreal (IVT) treatment burden in study eyes >67% reduction in anti-VEGF IVT treatment in fellow eyes of bilateral ...

For those who smoke, this long-term habit can damage parts of your eye, contributing to serious conditions such as macular degeneration. According to experts, AMD has no cure and can only worsen over ...

Bayer submitted an application to the European Medicines Agency (EMA) to expand treatment intervals of up to 6 months with Eylea™ 8 mg (aflibercept 8 mg, ...